Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - Ultragenyx reported a quarterly loss of $1.57 per share, slightly worse than the Zacks Consensus Estimate of a loss of$1.54, but an improvement from a loss of $2.03 per share a year ago, indicating a year-over-year improvement in loss figures [1] - The company posted revenues of$139.29 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.90%, but showing an increase from $108.83 million in the same quarter last year [2] - Over the last four quarters, Ultragenyx has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Ultragenyx shares have declined approximately 7.6$1.27 on revenues of $160.05 million, and for the current fiscal year, it is -$5.14 on revenues of $653.73 million [7] - The estimate revisions trend for Ultragenyx is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Ultragenyx belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ultragenyx's stock performance [5]